Acorda acquires NeurogesX's pain patch and liquid for up to $12M

04/18/2013 | American City Business Journals

NeurogesX sold its Qutenza pain patch and an investigational liquid formulation called NGX-1998 to Acorda Therapeutics. NeurogesX will receive $7 million upfront, an additional $2 million if NGX-1998 wins FDA approval plus $3 million contingent on the drug's first-year sales hitting $100 million. The deal does not cover Europe, the Middle East or Africa, where Astellas Pharma holds marketing rights.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY